|
|
|
|
|
Sildenafil: profile and news
Chinese Herbal Medicines 16 May 2006 A fairy tale of a drug May 13, 2006 What do we know about the links between recreational drug use ... May 15, 2006 Viagra may help children with fatal lung disorder May 8, 2006 Recent studies from Germany and the United States add new data to ... May 8, 2006 Cialis Is Effective In The Treatment Of Men With Erectile ... Apr 24, 2006 Health Canada Issues Warning of Serious Health Risks Posed By ... May 7, 2006 Warning - Health Canada warns consumers not to use Nasutra due to ... May 3, 2006 Fake Viagra maker given 10-year prison term May 9, 2006 Long Term Use Of Oral PDE-5 Inhibitors May Treat And Prevent ... Apr 18, 2006 Optic Neuropathy Patients Should Avoid Erectile Dysfunction Drugs May 1, 2006 Vitamin V(iagra) – ultimate sexual power booster May 12, 2006 The Medical Company Offers Ability to Buy Cheap Viagra, Cheap ... Apr 23, 2006 Potential new usage for Viagra May 1, 2006 Generic Viagra suiting a common man’s purse Apr 26, 2006 Spark your sexual life with Viagra May 4, 2006 CoTherix Reports First Quarter Results May 3, 2006 Drugs seized in horse racing probe Apr 24, 2006 Horse dopers busted Apr 25, 2006 Warning On Medicines Apr 26, 2006 Ensure Quality Sexual Health with Viagra Apr 19, 2006 Men’s Health – Don’t ignore it Apr 27, 2006 ORC Raids Drug Supplier Apr 20, 2006 Cialis Is Effective In The Treatment Of Men With Erectile ... Apr 25, 2006 Love’sa step ahead of MS Apr 24, 2006 Other information Indication For the treatment of erectile dysfunction Pharmacology Sildenafil is used to treat male erectile dysfunction (impotence) and pulmonary arterial hypertension (PAH). Part of the physiological process of erection involves the release of nitric oxide (NO) in the corpus cavernosum. This then activates the enzyme guanylate cyclase which results in increased levels of cyclic guanosine monophosphate (cGMP), leading to smooth muscle relaxation in the corpus cavernosum, resulting in increased inflow of blood and an erection. Sildenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum. This means that, with Sildenafil on board, normal sexual stimulation leads to increased levels of cGMP in the corpus cavernosum which leads to better erections. Without sexual stimulation and no activation of the NO/cGMP system, Sildenafil should not cause an erection. Mechanism Of Action Sildenafil inhibits the cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum located around the penis. Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) by Sildenafil enhances erectile function by increasing the amount of cGMP. Drug Category Vasodilator Agents; Phosphodiesterase Inhibitors; ATC:G04BE03 Brand Names/Synonyms Sildenafil; Sildenafil Viagra; Viagra Dosage Forms TABLET Absorption ~40% Interactions -->Interactions for Sildenafil: Effects of Other Drugs on Sildenafil Citrate In Vitro Studies: Sildenafil metabolism is principally mediated by the cytochrome P450 (CYP) isoforms 3A4 (major route) and 2C9 (minor route). Therefore, inhibitors of these isoenzymes may reduce sildenafil clearance. In Vivo Studies: Cimetidine (800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma sildenafil concentrations when coadministered with sildenafil citrate (50 mg) to healthy volunteers. When a single 100 mg dose of sildenafil citrate was administered with erythromycin, a specific CYP3A4 inhibitor, at steady state (500 mg bid for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC). In addition, coadministration of the HIV protease inhibitor saquinavir, also a CYP3A4 inhibitor, at steady state (1200 mg tid) with sildenafil citrate (100 mg single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC. Sildenafil citrate had no effect on saquinavir pharmacokinetics. Stronger CYP3A4 inhibitors such as ketoconazole or itraconazole would be expected to have still greater effects, and population data from patients in clinical trials did indicate a reduction in sildenafil clearance when it was coadministered with CYP3A4 inhibitors (such as ketoconazole, erythromycin, or cimetidine). Coadministration with the HIV protease inhibitor ritonavir, which is a highly potent P450 inhibitor, at steady state (400 mg bid) with sildenafil citrate (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1000% (11-fold) increase in sildenafil plasma AUC. At 24 hours the plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was dosed alone. This is consistent with ritonavir's marked effects on a broad range of P450 substrates. Sildenafil citrate had no effect on ritonavir pharmacokinetics. It can be expected that concomitant administration of CYP3A4 inducers, such as rifampin, will decrease plasma levels of sildenafil. Single doses of antacid (magnesium hydroxide/aluminum hydroxide) did not affect the bioavailability of sildenafil citrate. Pharmacokinetic data from patients in clinical trials showed no effect on sildenafil pharmacokinetics of CYP2C9 inhibitors (such as tolbutamide, warfarin), CYP2D6 inhibitors (such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related diuretics, ACE inhibitors, and calcium channel blockers. The AUC of the active metabolite, N-desmethyl sildenafil, was increased 62% by loop and potassium-sparing diuretics and 102% by nonspecific beta-blockers. These effects on the metabolite are not expected to be of clinical consequence. Effects of Sildenafil Citrate on Other Drugs In Vitro Studies: Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 (IC50 >150 mM). Given sildenafil peak plasma concentrations of approximately 1 mcM after recommended doses, it is unlikely that sildenafil citrate will alter the clearance of substrates of these isoenzymes. In Vivo Studies: When sildenafil citrate 100 mg oral was coadministered with amlodipine, 5 mg or 10 mg oral, to hypertensive patients, the mean additional reduction on supine blood pressure was 8 mmHg systolic and 7 mmHg diastolic. No significant interactions were shown with tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolized by CYP2C9. Sildenafil citrate (50 mg) did not potentiate the increase in bleeding time caused by aspirin (150 mg). Sildenafil citrate (50 mg) did not potentiate the hypotensive effect of alcohol in healthy volunteers with mean maximum blood alcohol levels of 0.08%. Sildenafil (100 mg) did not affect the steady state pharmacokinetics of the HIV protease inhibitors, saquinavir and ritonavir, both of which are CYP3A4 substrates. Chemical IUPAC Name 3-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonyl-phenyl]-7-methyl-9-propyl-2,4,7,8-tetrazabicyclo[4.3.0]nona-3,8,10-trien-5-one Chemical Formula C22H30N6O4S Half Life 4 hours Drug Type Approved Drug # Accession No APRD00556 CAS Registry Number 139755-83-2 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |